von Minckwitz G, et al. - In this phase 3, open-label trial, researchers estimated 1486 individuals to examine the outcome for trastuzumab emtansine (T-DM1) vs cytotoxic agent emtansine (DM1) in residual invasive human epidermal growth factor receptor 2 (HER2)-positive breast cancer. They observed that 88.3% in the T-DM1 group and 77.0% in the trastuzumab group were free of invasive disease at 3 years. They also found distant recurrence (the first invasive-disease event) in 10.5% of cases in the T-DM1 group and 15.9% of those in the trastuzumab group. They concluded a 50% lesser risk of recurrence of invasive breast cancer or death with adjuvant T-DM1 than with trastuzumab alone among females with HER2-positive early breast cancer and residual invasive disease after completion of neoadjuvant therapy.